Oesophageal Health Test vs Endoscopy:

• Simple, non-invasive blood test vs invasive procedure
• Quick test vs potentially a long waiting period for the endoscopy to be scheduled and having to take time off work
• Results within 2 to 4 weeks vs potentially a long waiting time for the endoscopy to be scheduled as well as 1-3 weeks for the results

Endoscopy also requires:

• Fasting the night prior to procedure
• Someone to drive the patient home from the hospital/clinic after the procedures.

Cost benefits

Private health insurance patients also face significant co-payment for their endoscopy procedure, as well as their GI specialist office visit(s).

People with chronic acid reflux (also known as Gastro-oesophageal Reflux Disease - GORD) who are discussing endoscopy with their doctor to rule out a common type of oesophageal cancer called oesophageal adenocarcinoma.

Suitable candidates include people who have been diagnosed with Barrett’s oesophagus who are on surveillance endoscopy.

Eligibility criteria for this test include:

• No prior cancer diagnosis
• Frequent heartburn or chronic acid reflux (GORD)
• At least one risk factors for oesophageal adenocarcinoma, including:
• Age > 50 years
• Overweight (BMI > 25 kg/m2)

The test measures four glycoprotein biomarkers in the blood, and these measurements are then combined with age, sex and BMI in a statistical model to assess your risk of oesophageal adenocarcinoma.

The test results use a traffic light system to classify your risk of oesophageal adenocarcinoma:

• Green = low risk of oesophageal adenocarcinomao
• Amber = moderate risk of oesophageal adenocarcinoma
• Red = high risk of oesophageal adenocarcinoma

The oesophageal Health Test is a non-invasive blood test for the detection of oesophageal cancer. It identifies 4 biomarkers in the blood that are linked with this type of cancer, then combines this with age and body mass index (BMI) data to calculate a risk score. Clinical studies validating this test have reported high accuracy, with the test's ability to "rule out" oesophageal cancer with a 99.9% negative predictive value¹¹.

To be eligible, you must not have had prior cancer diagnosis and exhibit frequent heartburn or acid reflux (also known as Gastro-Oesophageal Reflux Disease (GORD)).

You also need to have at least one of two risk factors for EAC (oesophageal adenocarcinoma), including:

• Age > 50 years

• Overweight BMI > 25 kg/m2

Follow these simple steps to take the oesophageal health test:

1. Download the test referral form.

2. Take the referral form to your health care provider to discuss your eligibility.

3. Take the signed referral form to a participating collection centre and have your blood sample taken.

4. Wait for your doctor to contact you.

The oesophageal health test costs $940, with a current introductory price of $440. As the test is new, it is not yet covered by Medicare.

Yes. You can get a referral from your preferred health care provider.

2 to 4 weeks depending on where you are located.

We know health information is sensitive and we take your privacy very seriously. Your test results are private and confidential.

Our laboratory system stores your personal information on highly secure, encrypted servers. This information is never shared with third parties without your explicit approval. See our Privacy Policy for further information.

1. Keung C, Hebbard G. The management of gastro-oesophageal reflux disease. Aust Prescr. 2016;39(1):6-10.
2. van Zanten SV. Chronic GERD and risk of esophageal adenocarcinoma: Should we screen with gastroscopy? CMAJ. 2020;192(27):E781-E782.
3. Tran CL, et al. Gastroesophageal reflux disease and risk of cancer: Findings from the Korean National Health Screening Cohort. Cancer Med. 2023;12(18):19163-19173.
4. McColl KE. What is causing the rising incidence of esophageal adenocarcinoma in the West and will it also happen in the East? J Gastroenterol 2019;54(8):669-673.
5. Rubenstein JH, Shaheen NJ. Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology 2015;149:302-317.
6. Bray F. et al, (2024) CA Cancer J Clin. 74(3), 229-263
7. Dam et al., (2020) Ann. Transl. Med., 8(17): 1107‍
8. Stawinski et al., (2023) Diagnostics (Basel). 13(2), 321.
9. Visrodia et al., (2016) Gastro., 150(3), 599-607.e7
10. https://www.proteomics.com.au/wp-content/uploads/240201-ASX-PIQ-Study-validates-biomarkers-for-oesophageal-cancer-blood-test.pdf
11. Sheahan J, et al., A Clinical Validation of a Diagnostic Test for Esophageal Adenocarci noma Based on a Novel Serum Glycoprotein Biomarker Panel: PromarkerEso. Proteomes (2025). 13(2), 23.